Nevertheless, anti-Rh(D) IgG as currently produced and used has been incredibly successful: The incidence of HDFN in at-risk pregnancies treated with anti-Rh(D) IgG has fallen to below 1% (96). This evidence concerns the gene RHD and fetal erythroblastosis.